A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ACC, AHA Issue Updated Chest Pain Data Standards

Chest pain is one of the leading reasons for adult emergency room visits in the United States, accounting for more than 7 million visits annually. Properly identifying and treating dangerous and life-threatening causes of chest pain is critical.

The 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Chest Pain underscored the need to reach a consensus for the definitions of chest pain. In an update to the 2021 guideline, this 2022 document standardizes related data elements for consistent reporting on chest pain cases and establishes a new definition set focusing on serious cardiovascular causes of chest pain and acute myocardial infarction.

Included in the document, data elements are grouped into three broad categories: chest pain, myocardial injury and myocardial infarction. Chest pain symptoms have traditionally been labeled “typical” or “atypical,” however, to define their expansive nature, the document divides chest pain syndromes into three categories: “cardiac,” “possible cardiac” and “noncardiac” based on the 2021 chest pain guideline. In addition, the writing committee writes that uniform definitions for myocardial infarction are needed to ensure accurate reporting of cardiac events across all clinical trials and registries. Data elements for procedure-related myocardial injury and procedure-related myocardial infarction are included in the document. The standardized definitions and data elements should be broadly applicable across patient care settings, electronic health records, quality and performance improvement initiatives, registries and public reporting programs.

The 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction will publish online in the Journal of the American College of Cardiology and Circulation: Cardiovascular Quality and Outcomes on Tuesday, August 30, 2022 at 2:00 p.m. ET. It was developed in collaboration with the American College of Emergency Physicians and the Society for Cardiac Angiography and Interventions, and endorsed by the Society for Academic Emergency Medicine.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy